Eledon Pharmaceuticals, Inc. - Common Stock (ELDN)

ELDN stock results show that Eledon Pharma missed analyst estimates for earnings per share the second quarter of 2024.

You don’t want to overlook these three penny stocks filled to the brim with the potential to make huge leaps in their respective markets.

Although the very idea of millionaire-maker penny stocks implies incredibly high risks, if all cylinders fire, these companies could fly.

ELDN stock results show that Eledon Pharma beat analyst estimates for earnings per share the first quarter of 2024.

Eledon Pharmaceuticals' results from islet cell transplant trial for type 1 diabetes, with tegoprubart showing safety and efficacy in kidney transplant patients. Analysts anticipate significant advancements, reflecting in raised price targets.

ELDN stock results show that Eledon Pharma beat analyst estimates for earnings per share the fourth quarter of 2023.

Eledon Pharmaceuticals announces successful use of tegoprubart in kidney xenotransplant. Promising results show its potential to prevent rejection, marking a significant milestone in organ transplantation research.

  On Tuesday, 56 companies set new 52-week lows.

  On Thursday, 64 companies achieved new lows for the year.

Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares rose 58.9% to $0.3754 in pre-market trading. Airspan Networks recently reported new financing and leadership changes.

It's time to start the day with a breakdown of the biggest pre-market stock movers that traders need to know about for Thursday morning!

Gainers Metacrine (NASDAQ:MTCR) shares rose 13.8% to $0.54 during Tuesday's after-market session. This security traded at a volume of 3.0 million shares come close, making up 948.6% of its average volume over the last 100 days. The company's market cap stands at $22.7 million.